101 related articles for article (PubMed ID: 21576405)
1. Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid.
Schmidt M; Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(3):325-33. PubMed ID: 21576405
[TBL] [Abstract][Full Text] [Related]
2. In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.
Kim Y; Gast SM; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2012 May; 36(5):598-600. PubMed ID: 22386728
[TBL] [Abstract][Full Text] [Related]
3. Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.
Kim Y; Schmidt M; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(6):887-93. PubMed ID: 22021681
[TBL] [Abstract][Full Text] [Related]
4. In vivo efficacy of griseofulvin against multiple myeloma.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Leuk Res; 2011 Aug; 35(8):1070-3. PubMed ID: 21112630
[TBL] [Abstract][Full Text] [Related]
5. Current status of new drugs for the treatment of patients with multiple myeloma.
Kenealy M; Prince HM
Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
[TBL] [Abstract][Full Text] [Related]
6. Increased in vivo efficacy of lenalidomide by addition of piroctone olamine.
Kim Y; Alpmann P; Blaum-Feder S; Krämer S; Endo T; Lu D; Carson D; Schmidt-Wolf IG
In Vivo; 2011; 25(1):99-103. PubMed ID: 21282741
[TBL] [Abstract][Full Text] [Related]
7. Multiple myeloma.
Kyle RA; Rajkumar SV
N Engl J Med; 2004 Oct; 351(18):1860-73. PubMed ID: 15509819
[No Abstract] [Full Text] [Related]
8. Targeting Wnt pathway in lymphoma and myeloma cells.
Schmidt M; Sievers E; Endo T; Lu D; Carson D; Schmidt-Wolf IG
Br J Haematol; 2009 Mar; 144(5):796-8. PubMed ID: 19036118
[No Abstract] [Full Text] [Related]
9. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide.
De Matteo M; Brunetti AE; Maiorano E; Cafforio P; Dammacco F; Silvestris F
Leuk Res; 2010 Feb; 34(2):243-9. PubMed ID: 19656567
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the mevalonate pathway potentiates the effects of lenalidomide in myeloma.
van der Spek E; Bloem AC; Lokhorst HM; van Kessel B; Bogers-Boer L; van de Donk NW
Leuk Res; 2009 Jan; 33(1):100-8. PubMed ID: 18621417
[TBL] [Abstract][Full Text] [Related]
11. In vitro cytotoxicity of the novel antimyeloma agents perifosine, bortezomib and lenalidomide against different cell lines.
Schmidt-Hieber M; Dabrowski R; Weimann A; Aicher B; Lohneis P; Busse A; Thiel E; Blau IW
Invest New Drugs; 2012 Apr; 30(2):480-9. PubMed ID: 21080211
[TBL] [Abstract][Full Text] [Related]
12. Near-tetraploidy clone can evolve from a hyperdiploidy clone and cause resistance to lenalidomide and bortezomib in a multiple myeloma patient.
Yuan J; Shah R; Kulharya A; Ustun C
Leuk Res; 2010 Jul; 34(7):954-7. PubMed ID: 20138360
[TBL] [Abstract][Full Text] [Related]
13. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
[TBL] [Abstract][Full Text] [Related]
14. Targeting the Wnt/beta-catenin pathway in multiple myeloma.
Schmeel LC; Schmeel FC; Kim Y; Endo T; Lu D; Schmidt-Wolf IG
Anticancer Res; 2013 Nov; 33(11):4719-26. PubMed ID: 24222106
[TBL] [Abstract][Full Text] [Related]
15. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
16. MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.
Asvadi P; Cuddihy A; Dunn RD; Jiang V; Wong MX; Jones DR; Khong T; Spencer A
Br J Haematol; 2015 May; 169(3):333-43. PubMed ID: 25653020
[TBL] [Abstract][Full Text] [Related]
17. Targeting multiple myeloma cells and their bone marrow microenvironment.
Pagnucco G; Cardinale G; Gervasi F
Ann N Y Acad Sci; 2004 Dec; 1028():390-9. PubMed ID: 15650264
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
[TBL] [Abstract][Full Text] [Related]
19. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model.
LeBlanc R; Catley LP; Hideshima T; Lentzsch S; Mitsiades CS; Mitsiades N; Neuberg D; Goloubeva O; Pien CS; Adams J; Gupta D; Richardson PG; Munshi NC; Anderson KC
Cancer Res; 2002 Sep; 62(17):4996-5000. PubMed ID: 12208752
[TBL] [Abstract][Full Text] [Related]
20. Lenalidomide and thalidomide: mechanisms of action--similarities and differences.
Anderson KC
Semin Hematol; 2005 Oct; 42(4 Suppl 4):S3-8. PubMed ID: 16344099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
